General Information of Drug (ID: DMIJC9X)

Drug Name
Osilodrostat Drug Info
Synonyms
LCI699; 928134-65-0; LCI-699; UNII-5YL4IQ1078; CHEMBL3099695; 5YL4IQ1078; Osilodrostat;4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile; 1304733-26-3; Osilodrostat [USAN:INN]; LCI 699; Osilodrostat (USAN/INN); LCI699-NX; GTPL8310; SCHEMBL12460772; DTXSID40156570; MolPort-044-560-410; EX-A1397; ZINC72318114; s7456; BDBM50444549; AKOS027323750; DB11837; CS-6896; HY-16276; KB-78108; Z-3271; D11061; 4-[(5R)-6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzo nitrile
Indication
Disease Entry ICD 11 Status REF
Cushing disease 5A70 Approved [1]
Cross-matching ID
PubChem CID
44139752
CAS Number
CAS 928134-65-0
TTD Drug ID
DMIJC9X
ACDINA Drug ID
D01304

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
FADROZOLE DM3C5GZ Breast cancer 2C60-2C65 Approved [2]
Metyrapone DMI7FVQ Cushing disease 5A70 Approved [3]
4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol DM6Z5EK Discovery agent N.A. Investigative [4]
4-Indan-(1Z)-ylidenemethyl-pyridine DM25DR7 Discovery agent N.A. Investigative [5]
4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine DMIEMWA Discovery agent N.A. Investigative [4]
4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine DMY08FE Discovery agent N.A. Investigative [5]
5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine DM2RIHT Discovery agent N.A. Investigative [5]
4-((1H-imidazol-1-yl)methyl)benzonitrile DMFUBRC Discovery agent N.A. Investigative [2]
4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine DMHDZUO Discovery agent N.A. Investigative [5]
4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine DMQKHXN Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Steroid 11-beta-hydroxylase (CYP11B1) TTIQUX7 C11B1_HUMAN Modulator [1]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
3 Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. Toxicol In Vitro. 2002 Apr;16(2):113-21.
4 Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
5 Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.